JP7299021B2 - 生体関連の直交性サイトカイン/受容体ペア - Google Patents

生体関連の直交性サイトカイン/受容体ペア Download PDF

Info

Publication number
JP7299021B2
JP7299021B2 JP2018513275A JP2018513275A JP7299021B2 JP 7299021 B2 JP7299021 B2 JP 7299021B2 JP 2018513275 A JP2018513275 A JP 2018513275A JP 2018513275 A JP2018513275 A JP 2018513275A JP 7299021 B2 JP7299021 B2 JP 7299021B2
Authority
JP
Japan
Prior art keywords
cells
cell
orthogonal
receptor
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018513275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018526020A (ja
Inventor
クリストファー ガルシア,ケナン
ソッカロスキー,ジョナサン
ベイカー,デイヴィッド
キング,クリス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WASHINGTON, University of
Original Assignee
WASHINGTON, University of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58240003&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7299021(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by WASHINGTON, University of filed Critical WASHINGTON, University of
Publication of JP2018526020A publication Critical patent/JP2018526020A/ja
Priority to JP2021180486A priority Critical patent/JP7495385B2/ja
Application granted granted Critical
Publication of JP7299021B2 publication Critical patent/JP7299021B2/ja
Priority to JP2024013400A priority patent/JP2024054175A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
JP2018513275A 2015-09-11 2016-09-07 生体関連の直交性サイトカイン/受容体ペア Active JP7299021B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021180486A JP7495385B2 (ja) 2015-09-11 2021-11-04 生体関連の直交性サイトカイン/受容体ペア
JP2024013400A JP2024054175A (ja) 2015-09-11 2024-01-31 生体関連の直交性サイトカイン/受容体ペア

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562217364P 2015-09-11 2015-09-11
US62/217,364 2015-09-11
US201662375089P 2016-08-15 2016-08-15
US62/375,089 2016-08-15
PCT/US2016/050511 WO2017044464A1 (en) 2015-09-11 2016-09-07 Biologically relevant orthogonal cytokine/receptor pairs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021180486A Division JP7495385B2 (ja) 2015-09-11 2021-11-04 生体関連の直交性サイトカイン/受容体ペア

Publications (2)

Publication Number Publication Date
JP2018526020A JP2018526020A (ja) 2018-09-13
JP7299021B2 true JP7299021B2 (ja) 2023-06-27

Family

ID=58240003

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018513275A Active JP7299021B2 (ja) 2015-09-11 2016-09-07 生体関連の直交性サイトカイン/受容体ペア
JP2020571337A Active JP7846963B2 (ja) 2015-09-11 2019-03-08 生物学的に関連する直交サイトカイン/受容体対
JP2021180486A Active JP7495385B2 (ja) 2015-09-11 2021-11-04 生体関連の直交性サイトカイン/受容体ペア
JP2023204147A Pending JP2024037778A (ja) 2015-09-11 2023-12-01 生物学的に関連する直交サイトカイン/受容体対
JP2024013400A Pending JP2024054175A (ja) 2015-09-11 2024-01-31 生体関連の直交性サイトカイン/受容体ペア

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020571337A Active JP7846963B2 (ja) 2015-09-11 2019-03-08 生物学的に関連する直交サイトカイン/受容体対
JP2021180486A Active JP7495385B2 (ja) 2015-09-11 2021-11-04 生体関連の直交性サイトカイン/受容体ペア
JP2023204147A Pending JP2024037778A (ja) 2015-09-11 2023-12-01 生物学的に関連する直交サイトカイン/受容体対
JP2024013400A Pending JP2024054175A (ja) 2015-09-11 2024-01-31 生体関連の直交性サイトカイン/受容体ペア

Country Status (17)

Country Link
US (7) US10869887B2 (cg-RX-API-DMAC7.html)
EP (2) EP3347056A4 (cg-RX-API-DMAC7.html)
JP (5) JP7299021B2 (cg-RX-API-DMAC7.html)
KR (3) KR20250004916A (cg-RX-API-DMAC7.html)
CN (4) CN108430518A (cg-RX-API-DMAC7.html)
AR (1) AR114687A1 (cg-RX-API-DMAC7.html)
AU (4) AU2016318621A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020018293A2 (cg-RX-API-DMAC7.html)
CA (2) CA2998393A1 (cg-RX-API-DMAC7.html)
HK (1) HK1258138A1 (cg-RX-API-DMAC7.html)
IL (2) IL277118B2 (cg-RX-API-DMAC7.html)
MX (1) MX428362B (cg-RX-API-DMAC7.html)
PH (1) PH12020551417A1 (cg-RX-API-DMAC7.html)
RU (1) RU2020133171A (cg-RX-API-DMAC7.html)
SG (1) SG11202008780SA (cg-RX-API-DMAC7.html)
WO (2) WO2017044464A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006168B (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7299021B2 (ja) * 2015-09-11 2023-06-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 生体関連の直交性サイトカイン/受容体ペア
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2020131547A1 (en) * 2018-12-19 2020-06-25 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
MX2021011258A (es) * 2019-03-18 2021-12-10 Biontech Cell & Gene Therapies Gmbh Variantes de interleucina-2 (il2) y receptor de interleucina-2 (il2r) para la activacion especifica de celulas efectoras inmunitarias.
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
CN114555634B (zh) * 2019-08-13 2025-01-10 美国安进公司 用于扩增调节性t细胞的白介素-2突变蛋白
WO2021050752A1 (en) * 2019-09-11 2021-03-18 The Board Of Trustees Of The Leland Stanford Junior University Chimeric orthogonal receptor proteins and methods of use
CA3151471A1 (en) * 2019-10-08 2021-04-15 Gesa VOLKERS Modified extracellular domain of granulocyte colony-stimulating factor receptor (g-csfr) and cytokines binding same
US11648296B2 (en) * 2019-12-13 2023-05-16 Synthekine, Inc. IL-2 orthologs and methods of use
IL293978A (en) * 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
CN115315273A (zh) * 2020-01-14 2022-11-08 辛德凯因股份有限公司 Il-2直向同源物及其使用方法
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
KR20220131529A (ko) * 2020-01-14 2022-09-28 신테카인, 인크. 변경된 icd stat 신호전달을 갖는 cd122
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
BR112022017656A2 (pt) * 2020-03-05 2022-10-18 Univ Leland Stanford Junior Variantes de il-2 concebidas
JP2023520572A (ja) * 2020-04-06 2023-05-17 シンセカイン インコーポレイテッド オルソゴナルな受容体を発現するようにゲノムが改変されたヒト免疫細胞
WO2021207290A1 (en) * 2020-04-06 2021-10-14 Synthekine, Inc. Engineered immune cells
KR20230060514A (ko) * 2020-09-01 2023-05-04 다케다 야쿠힌 고교 가부시키가이샤 인터루킨-2 뮤테인 및 이의 용도
CN116529257A (zh) * 2020-10-26 2023-08-01 尼普图恩生物科学有限公司 正交il-21受体/细胞因子系统
WO2022093683A1 (en) * 2020-10-26 2022-05-05 Neptune Biosciences Llc Orthogonal il-21 receptor/cytokine systems
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
EP4305054A4 (en) * 2021-03-09 2025-03-19 The Trustees of The University of Pennsylvania SELECTIVE STIMULATION OF T CELLS IN SOLID TUMORS USING ONCOLYTIC VIRAL ADMINISTRATION OF ORTHOGONAL IL-2
US20240182584A1 (en) * 2021-04-02 2024-06-06 The Board Of Trustees Of The Leland Stanford Junior University Bispecific Molecules and Related Compositions and Methods
WO2022213208A1 (en) * 2021-04-07 2022-10-13 Provincial Health Services Authority Modified granulocyte colony-stimulating factor (g-csf) and chimeric cytokine receptors binding same
KR20240034221A (ko) 2021-07-09 2024-03-13 브라이트 피크 테라퓨틱스 아게 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드
EP4370139A4 (en) * 2021-07-14 2025-10-15 Synthekine Inc METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY FOR NEOPLASTIC DISEASE
EP4402161A1 (en) 2021-09-17 2024-07-24 Parker Institute For Cancer Immunotherapy Switch receptors using il-9 signaling domains
PE20242341A1 (es) * 2022-04-04 2024-12-12 Gammadelta Therapeutics Ltd Blindaje genetico novedoso
EP4293040A1 (en) 2022-06-19 2023-12-20 ETH Zurich Cell line for engineering cytokine receptors
CN121013867A (zh) * 2023-06-07 2025-11-25 Fbd生物制品有限公司 工程化的il-7变体及其使用方法
WO2025245495A1 (en) * 2024-05-24 2025-11-27 Cz Biohub Sf, Llc Selective sensitization of cancer cells to elimination by cytotoxic lymphocytes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506980A (ja) 1998-03-20 2002-03-05 ジェンザイム・コーポレーション 新規の相補的レセプター−リガンド対およびそれを使用する養子免疫療法
JP2005511707A (ja) 2001-12-04 2005-04-28 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 調節された選択性を有する免疫サイトカイン

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US7666400B2 (en) 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US6926898B2 (en) * 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
US20060199250A1 (en) * 2005-03-04 2006-09-07 Huimin Zhao Method for generating a mutant protein which efficiently binds a target molecule
JP2009542592A (ja) 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Il−2媒介性免疫応答の有効性を高める組成物および方法
JP5703020B2 (ja) 2007-08-24 2015-04-15 ノボ ノルディスク ヘルス ケア アーゲー タンパク質を選択的に修飾するための組成物と方法
EP2560994B1 (en) * 2010-04-08 2016-10-12 JN Biosciences LLC Antibodies to cd122
WO2013074916A1 (en) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
LT2884999T (lt) * 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
US9434935B2 (en) * 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
EP2968450A4 (en) 2013-03-15 2016-10-26 Angelica Therapeutics Inc MODIFIED TOXINS
SI2997141T1 (sl) 2013-05-13 2023-04-28 Cellectis CD19 specifični himerni antigenski receptor in njegova uporaba
JP6640834B2 (ja) 2014-08-11 2020-02-05 デリニア, インコーポレイテッド 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体
IL304950A (en) * 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
JP7299021B2 (ja) * 2015-09-11 2023-06-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 生体関連の直交性サイトカイン/受容体ペア
CN107746831B (zh) 2017-11-07 2019-04-23 南京北恒生物科技有限公司 具有化疗药物抗性的通用型cart/tcrt细胞及其构建方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506980A (ja) 1998-03-20 2002-03-05 ジェンザイム・コーポレーション 新規の相補的レセプター−リガンド対およびそれを使用する養子免疫療法
JP2005511707A (ja) 2001-12-04 2005-04-28 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 調節された選択性を有する免疫サイトカイン

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ring A et al,Mechanistic and Structural Insight into the Functional Dichotomy between Interleukin-2 and Interleukin-15,Nat Immunol,2012年,Vol.13,No.12,p.1187-1195
Wang X et al,Structure of the Quaternary Complex of interleukin-2 With Its α, β, and γc Receptors,Science,2005年,Vol.310,p.1159-1163

Also Published As

Publication number Publication date
JP2024054175A (ja) 2024-04-16
AU2023203727A1 (en) 2023-07-06
JP2021516996A (ja) 2021-07-15
CN108430518A (zh) 2018-08-21
IL277118B2 (en) 2024-12-01
US10869887B2 (en) 2020-12-22
JP2022025129A (ja) 2022-02-09
CN117659160A (zh) 2024-03-08
US20240374645A1 (en) 2024-11-14
SG11202008780SA (en) 2020-10-29
ZA202006168B (en) 2022-01-26
AU2026205249A1 (en) 2026-07-23
US20210069243A1 (en) 2021-03-11
EP3347056A4 (en) 2019-02-27
CN120209111A (zh) 2025-06-27
EP3761997A4 (en) 2022-08-03
KR20180049080A (ko) 2018-05-10
KR20210062591A (ko) 2021-05-31
US20260108586A1 (en) 2026-04-23
US11439664B2 (en) 2022-09-13
CA3093472A1 (en) 2019-09-12
US12005079B2 (en) 2024-06-11
AU2019231997A1 (en) 2020-10-15
WO2017044464A1 (en) 2017-03-16
US20190183933A1 (en) 2019-06-20
US20220354893A1 (en) 2022-11-10
JP7846963B2 (ja) 2026-04-16
WO2019173773A1 (en) 2019-09-12
JP2018526020A (ja) 2018-09-13
JP7495385B2 (ja) 2024-06-04
AU2023203727B2 (en) 2026-04-09
TW202017576A (zh) 2020-05-16
IL313413A (en) 2024-08-01
CN112272560B (zh) 2025-03-14
AU2019231997B2 (en) 2025-12-11
MX2020009330A (es) 2021-02-26
CN112272560A (zh) 2021-01-26
US20210060068A1 (en) 2021-03-04
KR102739782B1 (ko) 2024-12-09
HK1258138A1 (zh) 2019-11-08
BR112020018293A2 (pt) 2020-12-29
AU2016318621A1 (en) 2018-05-10
PH12020551417A1 (en) 2021-09-01
RU2020133171A (ru) 2022-04-12
MX428362B (es) 2025-11-13
JP2024037778A (ja) 2024-03-19
US20180228842A1 (en) 2018-08-16
EP3347056A1 (en) 2018-07-18
IL277118B1 (en) 2024-08-01
NZ741548A (en) 2025-05-30
KR20250004916A (ko) 2025-01-08
AR114687A1 (es) 2020-10-07
CA2998393A1 (en) 2017-03-16
IL277118A (en) 2020-10-29
EP3761997A1 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
JP7495385B2 (ja) 生体関連の直交性サイトカイン/受容体ペア
AU2020346824B2 (en) Chimeric orthogonal receptor proteins and methods of use
JP2023511274A (ja) Il2オルソログおよび使用法
HK40080067A (en) Chimeric orthogonal receptor proteins and methods of use

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190809

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211104

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211104

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20211116

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211213

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211214

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220121

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220125

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221108

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20221220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230317

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20230404

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230615

R150 Certificate of patent or registration of utility model

Ref document number: 7299021

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250